AIMS/HYPOTHESIS: Recent evidence links the soluble urokinase plasminogen activator receptor (suPAR), a stable biomarker of systemic immune activation, to several chronic diseases, including type 2 diabetes. suPAR is also associated with adiposity and smoking. We hypothesised that this biomarker would be linked to incident type 2 diabetes in individuals with impaired glucose regulation and that this association would be modified by smoking and body weight status. METHODS: The study included 1,933 participants with impaired glucose regulation, who were drawn from the Danish arm of the Anglo-Danish-Dutch Study of Intensive Treatment in People with Screen-Detected Diabetes in Primary Care (ADDITION) and for whom data on suPAR, BMI and smoking were available. Logistic regression analysis was used to estimate the odds for incident type 2 diabetes per twofold increase in suPAR levels. Interactions between both smoking and body weight status and suPAR were tested. RESULTS: During a 3-year follow-up (599 incident diabetes cases), there was a 48% overall increase in the odds of developing type 2 diabetes per twofold increase in suPAR (p = 0.006). This association was modified by body weight status in overweight, but not in obese individuals (OR 2.36, 95% CI 1.48, 3.76 in overweight group), and by smoking status (OR 2.05, 95% CI 1.20, 3.51 in non-smokers). After adjustment for other diabetes risk factors, the association between suPAR and type 2 diabetes was attenuated in the whole sample and among non-smokers, but remained robust among overweight participants. CONCLUSIONS/ INTERPRETATION: suPAR may be a good novel biomarker for systemic sub-clinical inflammation and immune activation linked to incident type 2 diabetes risk in overweight individuals and non-smokers. The observed interactions with adiposity and smoking should be investigated further.
AIMS/HYPOTHESIS: Recent evidence links the soluble urokinase plasminogen activator receptor (suPAR), a stable biomarker of systemic immune activation, to several chronic diseases, including type 2 diabetes. suPAR is also associated with adiposity and smoking. We hypothesised that this biomarker would be linked to incident type 2 diabetes in individuals with impaired glucose regulation and that this association would be modified by smoking and body weight status. METHODS: The study included 1,933 participants with impaired glucose regulation, who were drawn from the Danish arm of the Anglo-Danish-Dutch Study of Intensive Treatment in People with Screen-Detected Diabetes in Primary Care (ADDITION) and for whom data on suPAR, BMI and smoking were available. Logistic regression analysis was used to estimate the odds for incident type 2 diabetes per twofold increase in suPAR levels. Interactions between both smoking and body weight status and suPAR were tested. RESULTS: During a 3-year follow-up (599 incident diabetes cases), there was a 48% overall increase in the odds of developing type 2 diabetes per twofold increase in suPAR (p = 0.006). This association was modified by body weight status in overweight, but not in obese individuals (OR 2.36, 95% CI 1.48, 3.76 in overweight group), and by smoking status (OR 2.05, 95% CI 1.20, 3.51 in non-smokers). After adjustment for other diabetes risk factors, the association between suPAR and type 2 diabetes was attenuated in the whole sample and among non-smokers, but remained robust among overweight participants. CONCLUSIONS/ INTERPRETATION:suPAR may be a good novel biomarker for systemic sub-clinical inflammation and immune activation linked to incident type 2 diabetes risk in overweight individuals and non-smokers. The observed interactions with adiposity and smoking should be investigated further.
Authors: V Primeau; L Coderre; A D Karelis; M Brochu; M-E Lavoie; V Messier; R Sladek; R Rabasa-Lhoret Journal: Int J Obes (Lond) Date: 2010-10-26 Impact factor: 5.095
Authors: S B Haugaard; O Andersen; T W Hansen; J Eugen-Olsen; A Linneberg; S Madsbad; M H Olsen; T Jørgensen; K Borch-Johnsen; J Jeppesen Journal: Diabet Med Date: 2012-04 Impact factor: 4.359
Authors: J Eugen-Olsen; O Andersen; A Linneberg; S Ladelund; T W Hansen; A Langkilde; J Petersen; T Pielak; L N Møller; J Jeppesen; S Lyngbaek; M Fenger; M H Olsen; P R Hildebrandt; K Borch-Johnsen; T Jørgensen; S B Haugaard Journal: J Intern Med Date: 2010-05-28 Impact factor: 8.989
Authors: Stig Lyngbæk; Thomas Sehestedt; Jacob L Marott; Tine W Hansen; Michael H Olsen; Ove Andersen; Allan Linneberg; Sten Madsbad; Steen B Haugaard; Jesper Eugen-Olsen; Jørgen Jeppesen Journal: Int J Cardiol Date: 2012-03-28 Impact factor: 4.164
Authors: Tae-Hyun Yoo; Christopher E Pedigo; Johanna Guzman; Mayrin Correa-Medina; Changli Wei; Rodrigo Villarreal; Alla Mitrofanova; Farah Leclercq; Christian Faul; Jing Li; Matthias Kretzler; Robert G Nelson; Markku Lehto; Carol Forsblom; Per-Henrik Groop; Jochen Reiser; George William Burke; Alessia Fornoni; Sandra Merscher Journal: J Am Soc Nephrol Date: 2014-06-12 Impact factor: 10.121
Authors: Alexi Vasbinder; Elizabeth Anderson; Husam Shadid; Hanna Berlin; Michael Pan; Tariq U Azam; Ibrahim Khaleel; Kishan Padalia; Chelsea Meloche; Patrick O'Hayer; Erinleigh Michaud; Tonimarie Catalan; Rafey Feroze; Pennelope Blakely; Christopher Launius; Yiyuan Huang; Lili Zhao; Lynn Ang; Monica Mikhael; Kara Mizokami-Stout; Subramaniam Pennathur; Matthias Kretzler; Sven H Loosen; Athanasios Chalkias; Frank Tacke; Evangelos J Giamarellos-Bourboulis; Jochen Reiser; Jesper Eugen-Olsen; Eva L Feldman; Rodica Pop-Busui; Salim S Hayek; Salim S Hayek; Pennelope Blakely; Hanna Berlin; Tariq U Azam; Husam Shadid; Michael Pan; Patrick O'Hayer; Chelsea Meloche; Rafey Feroze; Kishan J Padalia; Elizabeth Anderson; Danny Perry; Abbas Bitar; Rayan Kaakati; Yiyuan Huang; Lili Zhao; Jochen Reiser; Beata Samelko; Alex Hlepas; Priya P Patel; Xuexiang Wang; Jesper Eugen-Olsen; Izzet Altintas; Marius Stauning; Morten Baltzer Houlind; Mette B Lindstrøm; Hejdi Gamst-Jensen; Line Jee Hartmann; Jan O Nehlin; Thomas Kallemose; Imran Parvaiz; Christian Rasmussen; Ove Andersen; Jens Tingleff; Evangelos J Giamarellos-Bourboulis; Maria-Evangelia Adami; Nicky Solomonidi; Maria Tsilika; Maria Saridaki; Vasileios Lekakis; Sven H Loosen; Tom Luedde; Verena Keitel; Athanasios Chalkias; Eleni Arnaoutoglou; Ioannis Pantazopoulos; Eleni Laou; Konstantina Kolonia; Anargyros Skoulakis; Frank Tacke; Pinkus Tober-Lau; Raphael Mohr; Florian Kurth; Leif Erik Sander; Christoph Jochum Journal: Diabetes Care Date: 2022-03-01 Impact factor: 19.112
Authors: R Barić Rafaj; J Kuleš; A Marinculić; A Tvarijonaviciute; J Ceron; Ž Mihaljević; A Tumpa; V Mrljak Journal: BMC Vet Res Date: 2017-01-06 Impact factor: 2.741
Authors: Martina Guthoff; Robert Wagner; Elko Randrianarisoa; Erifili Hatziagelaki; Andreas Peter; Hans-Ulrich Häring; Andreas Fritsche; Nils Heyne Journal: Sci Rep Date: 2017-01-16 Impact factor: 4.379
Authors: Salim S Hayek; Jasmin Divers; Mohamad Raad; Jianzhao Xu; Donald W Bowden; Melissa Tracy; Jochen Reiser; Barry I Freedman Journal: J Am Heart Assoc Date: 2018-05-01 Impact factor: 5.501
Authors: María Florencia Zacarías; María Carmen Collado; Carlos Gómez-Gallego; Heini Flinck; Janne Aittoniemi; Erika Isolauri; Seppo Salminen Journal: PLoS One Date: 2018-07-13 Impact factor: 3.240